Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer-In Reply

JAMA Oncol. 2019 Jul 1;5(7):1066-1067. doi: 10.1001/jamaoncol.2019.1100.

Authors

Steven D Criss¹, Meghan J Mooradian^{2

3}, Chung Yin Kong^{1

3}

Affiliations

¹ Institute for Technology Assessment, Massachusetts General Hospital, Boston.
² Massachusetts General Hospital Cancer Center, Boston.
³ Harvard Medical School, Boston, Massachusetts.

PMID: 31095247
DOI: 10.1001/jamaoncol.2019.1100

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal
Carcinoma, Non-Small-Cell Lung*
Chemoradiotherapy
Consolidation Chemotherapy
Cost-Benefit Analysis
Humans
Lung Neoplasms*

Substances

Antibodies, Monoclonal
durvalumab